非肽类促性腺激素释放激素拮抗剂在子宫肌瘤治疗中的应用研究进展  

Progress in the application of non-peptide gonadotropin-releasing hormone antagonist in the treatment of uterine fibroid

作　　者：郑韵熹 易晓芳[1] 徐丛剑[1] ZHENG Yunxi;YI Xiaofang;XU Congjian(Obstetrics&Gynecology Hospital of Fudan University,Shanghai 200011,China)

机构地区：[1]复旦大学附属妇产科医院,上海200011

出　　处：《中国临床药理学与治疗学》2024年第5期482-487,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

基　　金：国家重点研发计划“生育健康及妇女儿童健康保障”重点专项(2022YFC2704000)。

摘　　要：非肽类促性腺激素释放激素拮抗剂(gonadotropin-releasing hormone antagonist,GnRH-antagonist)作为GnRH受体的一种高效、选择性拮抗剂,其口服制剂(Elagolix,Relugolix及Linzagolix)已在国外获批上市,在用于子宫肌瘤缩小肌瘤体积、控制月经过多等方面展示了一定疗效,适当配伍反加治疗可以提高药物安全性与患者依从性,相比其他激素类制剂,口服GnRH拮抗剂在子宫肌瘤治疗中展示了良好的应用前景。Non-peptide gonadotropin-releasing hormone antagonist(GnRH-antagonist)is a highly efficient and selective antagonist of GnRH receptor.The oral preparations(Elagolix,Relugolix and Linzagolix)had been approved for listing abroad.It shows efficacy in reducing the size of uterine fibroid and controlling heavy bleeding.Appropriate combination of‘add-back’therapy could improve the safety in medical application and patient compliance.Compared with other hormonal pharmaceuticals,oral GnRH-antagonists showed promising prospects in the treatment of uterine fibroid.

关 键 词：促性腺激素释放激素拮抗剂 子宫肌瘤 治疗 有效性 安全性 

分 类 号：R711.71[医药卫生—妇产科学]